Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Briobacept (BR 3FC), a selective human monoclonal antibody, targets BLyS (BAFF) to induce B-cell apoptosis and is a recombinant glycoprotein comprising two BLyS receptor (BR3) molecules fused to the Fc domain of human IgG1. It has applications in the study of rheumatoid arthritis (RA) [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Briobacept (BR 3FC), a selective human monoclonal antibody, targets BLyS (BAFF) to induce B-cell apoptosis and is a recombinant glycoprotein comprising two BLyS receptor (BR3) molecules fused to the Fc domain of human IgG1. It has applications in the study of rheumatoid arthritis (RA) [1] [2]. |
In vitro | Briobacept inhibits B cell activation and induces apoptosis by blocking circulating BLyS [3]. |
In vivo | Briobacept, administered intraperitoneally at a dose of 100 µg/mouse for five consecutive days, suppresses basal NF-κB2 activity in wild-type mice [4]. Additionally, when given thrice weekly for a duration of five weeks, briobacept impedes p52 generation and the progression of spontaneous lupus-like disease in NZB/WF1 mice [4]. |
Synonyms | BR 3FC |
Molecular Weight | N/A |
CAS No. | 869881-54-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Briobacept 869881-54-9 BR 3FC inhibitor inhibit